A succinct review of botulinum toxin in dermatology; update of cosmetic and noncosmetic use

Feily, Amir; Fallahi, Hamidreza; Zandian, Dana; Kalantar, Hadi

doi:10.1111/j.1473-2165.2010.00545.x

Cited by 20 publications

(13 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study showed that triamcinolone acetonide used alone, or combined with BTA, provides similar clinical results in terms of scar improvement and symptomatic control. The results of our study confirmed the previous findings about the efficacy of triamcinolone on the keloids and some benefit of BTA on hypertrophic scars (Feily, Fallahi, Zandian, & Kalantar, ). Irradiation is mostly effective when administered in the adjuvant setting (i.e., after surgical excision) in which inhibitory effects on cell cycle and migration are optimized (Ramirez‐Fort et al, ).…”

Section: Discussionsupporting

confidence: 92%

Intralesional triamcinolone alone or in combination with botulinium toxin A is ineffective for the treatment of formed keloid scar: A double blind controlled pilot study

Rasaii

Sohrabian

Gianfaldoni

et al. 2019

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

Cutaneous injury can ignite excessive fibroproliferative growth that results in keloid formation. Keloids are associated with significant morbidity related to disfigurement and/or symptoms (e.g., pain and pruritus). First‐line treatment of formed keloids involves topical or intralesional steroids. Recurrent or resistant keloids are managed by surgical excision or cryotherapy, followed by steroidal application or adjuvant irradiation. Although adjuvant irradiation appears to be most efficacious, alternative therapeutic options are needed for patients without access to radiation centers. Botulinum Toxin A (BTA) appears to have similar inhibitory effects to irradiation on the cell cycle via downregulation of pathogenic cytokines. Herein, we conducted a study to compare the efficacy of intralesional triamcinolone used alone, or in combination with BTA, in the treatment of formed keloid scars. Twenty patients with a cumulative of 40 keloids completed the study. There was no significant difference between treatment arms with respect to height vascularization, pliability, and pigmentation scores. The addition of BTA resulted in significant symptomatic improvement of pain and pruritus as compared to intralesional triamcinolone alone (p < 0.001). Irradiation is only effective when administered in the adjuvant setting where inhibitory effects on cell cycle and migration are optimized. Future studies with intralesional triamcinolone and BTA should be performed adjuvantly.

show abstract

Section: Discussionsupporting

confidence: 92%

Intralesional triamcinolone alone or in combination with botulinium toxin A is ineffective for the treatment of formed keloid scar: A double blind controlled pilot study

Rasaii

Sohrabian

Gianfaldoni

et al. 2019

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…BTA has a wide variety of clinical applications in medical and dermatological sciences . In recent years, BTA has also been reported as a treatment measure for hypertrophic scars .…”

Section: Discussionmentioning

confidence: 99%

“…19 In recent years, BTA has also been reported as a treatment measure for hypertrophic scars. 19,20 The molecular mechanism by which BTA promotes healing of hypertrophic scars is not yet perfectly explained, but BTA has been shown to inhibit proliferation and promote apoptosis of fibroblasts derived from hypertrophic scars. 21,22 In addition, BTA was reported to reduce the expression of transforming growth factor beta-1 (TGF-β1).…”

Section: Discussionmentioning

confidence: 99%

Early postoperative treatment of thyroidectomy scars using botulinum toxin: A split‐scar, double‐blind randomized controlled trial

Kim¹,

Lee

Cho

et al. 2014

Wound Repair Regeneration

View full text Add to dashboard Cite

Operational scars, especially those located on the exposed parts of the body, can be distressing. Despite high demand for an early intervention to minimize surgical scars, there is yet no universal consensus on optimal treatment. A split-scar, double-blind randomized controlled trial was held to assess the safety and efficacy of early postoperative botulinum toxin type A (BTA) injection in surgical scars. A single session of treatment was performed where BTA was allocated to one half of the scar and 0.9% saline to the control half. Scars were assessed using the modified Stony Brook Scar Evaluation Scale (SBSES) with standardized photographs. Fifteen patients completed the study, and their data were analyzed. At 6 months' follow-up, a significant improvement in SBSES score was noted for the BTA-treated halves of the scars (p < 0.001), with minimal change on the saline-treated side (p = 0.785). The mean calculated difference in SBSES scores (final/initial) between the BTA-treated side and the saline-treated side was also significant (p < 0.001). Early postoperative BTA injection was safe and effective in modulating thyroidectomy scars and may be a promising option for scar prevention.

show abstract

“…Of these, 26 underwent full-text review and 17 were excluded [ 6 , 10 – 25 ]. Among these excluded studies, three were conducted on animals [ 11 – 13 ], four were case reports [ 14 , 16 , 18 , 21 ], three were reviews [ 6 , 10 , 17 ], and another seven lacked raw data or contained useless data [ 15 , 19 – 20 , 22 – 25 ] ( S1 File ). Finally, nine articles met the inclusion criteria and were included in the analysis [ 1 , 26 – 33 ].…”

Section: Resultsmentioning

confidence: 99%

Botulinum Toxin Type A and the Prevention of Hypertrophic Scars on the Maxillofacial Area and Neck: A Meta-Analysis of Randomized Controlled Trials

et al. 2016

View full text Add to dashboard Cite

BackgroundThe purpose of the meta-analysis was to evaluate the efficiency of therapeutic botulinum toxin type A (BTX-A) in the prevention of maxillofacial and neck scars.Methods and FindingsInformation came from the following electronic databases: Medline, PubMed, Cochrane Library, and EMBASE (time was ended by August 31, 2015) to retrieve RCTs evaluating the effect of the BTX-A for hypertrophic scar on the maxillofacial or neck. All languages were included as long as they met the inclusion criteria. Here the effects of BTX-A were evaluated by comparing the width of the scar, patient satisfaction, and the visual analysis scores (VAS), respectively. Pooled weighted mean differences (WMDs), pooled odds ratios (ORs), and 95% confidence intervals (CI) were calculated. Nine RCTs covering a total of 539 patients were included. A statistically significant difference in scar width was identified between the BTX-A group and control group (non-BTX-A used) (WMD = -0.41, 95% CI = -0.68 to -0.14, P = 0.003). A statistically significant difference in patient satisfaction was observed between the BTX-A group and control group (OR = 25.76, 95% CI = 2.58 to 256.67, P = 0.006). And in patients regarding visual analysis scores (VAS), a statistically significant difference was also observed between the BTX-A group and control group (WMD = 1.30, 95% CI = 1.00 to 1.60, P < 0.00001).ConclusionsThis meta-analysis evaluates the efficacy of the BTX-A and confirms that BTX-A is a suitable potential therapy for the prevention of hypertrophic scars in patients in the maxillofacial and neck areas.

show abstract

A succinct review of botulinum toxin in dermatology; update of cosmetic and noncosmetic use

Cited by 20 publications

References 62 publications

Intralesional triamcinolone alone or in combination with botulinium toxin A is ineffective for the treatment of formed keloid scar: A double blind controlled pilot study

Intralesional triamcinolone alone or in combination with botulinium toxin A is ineffective for the treatment of formed keloid scar: A double blind controlled pilot study

Early postoperative treatment of thyroidectomy scars using botulinum toxin: A split‐scar, double‐blind randomized controlled trial

Botulinum Toxin Type A and the Prevention of Hypertrophic Scars on the Maxillofacial Area and Neck: A Meta-Analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About